106 related articles for article (PubMed ID: 19013229)
21. The two enantiomers of tetrahydropalmatine are inhibitors of P-gp, but not inhibitors of MRP1 or BCRP.
Sun S; Chen Z; Li L; Sun D; Tian Y; Pan H; Bi H; Huang M; Zeng S; Jiang H
Xenobiotica; 2012 Dec; 42(12):1197-205. PubMed ID: 22900779
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of dual P-gp-BCRP inhibitors as nanoparticle formulation.
Singh MS; Juvale K; Wiese M; Lamprecht A
Eur J Pharm Sci; 2015 Sep; 77():1-8. PubMed ID: 25976226
[TBL] [Abstract][Full Text] [Related]
23. Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting.
Dahan A; Amidon GL
Am J Physiol Gastrointest Liver Physiol; 2009 Aug; 297(2):G371-7. PubMed ID: 19541926
[TBL] [Abstract][Full Text] [Related]
24. Interaction Studies of Resolvin E1 Analog (RX-10045) with Efflux Transporters.
Cholkar K; Trinh HM; Vadlapudi AD; Wang Z; Pal D; Mitra AK
J Ocul Pharmacol Ther; 2015 May; 31(4):248-55. PubMed ID: 25844889
[TBL] [Abstract][Full Text] [Related]
25. Interaction of thiazolidinediones (glitazones) with the ATP-binding cassette transporters P-glycoprotein and breast cancer resistance protein.
Weiss J; Sauer A; Herzog M; Böger RH; Haefeli WE; Benndorf RA
Pharmacology; 2009; 84(5):264-70. PubMed ID: 19776663
[TBL] [Abstract][Full Text] [Related]
26. Cannabidiol enhances xenobiotic permeability through the human placental barrier by direct inhibition of breast cancer resistance protein: an ex vivo study.
Feinshtein V; Erez O; Ben-Zvi Z; Eshkoli T; Sheizaf B; Sheiner E; Holcberg G
Am J Obstet Gynecol; 2013 Dec; 209(6):573.e1-573.e15. PubMed ID: 23933222
[TBL] [Abstract][Full Text] [Related]
27. Interactions of cyclosporin a with breast cancer resistance protein.
Xia CQ; Liu N; Miwa GT; Gan LS
Drug Metab Dispos; 2007 Apr; 35(4):576-82. PubMed ID: 17220244
[TBL] [Abstract][Full Text] [Related]
28. Functional expression of P-glycoprotein in primary cultures of human cytotrophoblasts and BeWo cells.
Utoguchi N; Chandorkar GA; Avery M; Audus KL
Reprod Toxicol; 2000; 14(3):217-24. PubMed ID: 10838122
[TBL] [Abstract][Full Text] [Related]
29. Interactions of tenofovir and tenofovir disoproxil fumarate with drug efflux transporters ABCB1, ABCG2, and ABCC2; role in transport across the placenta.
Neumanova Z; Cerveny L; Ceckova M; Staud F
AIDS; 2014 Jan; 28(1):9-17. PubMed ID: 24413260
[TBL] [Abstract][Full Text] [Related]
30. The multidrug resistance protein breast cancer resistance protein (BCRP) protects adipose-derived stem cells against ischemic damage.
van Dijk A; Naaijkens BA; Jurgens WJ; Oerlemans R; Scheffer GL; Kassies J; Aznou J; Brouwer M; van Rossum AC; Schuurhuis GJ; van Milligen FJ; Niessen HW
Cell Biol Toxicol; 2012 Oct; 28(5):303-15. PubMed ID: 22801743
[TBL] [Abstract][Full Text] [Related]
31. Interaction potential of the endothelin-A receptor antagonist atrasentan with drug transporters and drug-metabolising enzymes assessed in vitro.
Weiss J; Haefeli WE
Cancer Chemother Pharmacol; 2011 Oct; 68(4):1093-8. PubMed ID: 21805352
[TBL] [Abstract][Full Text] [Related]
32. Quantitative evaluation of the impact of active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier on the predictability of the unbound concentrations of drugs in the brain using cerebrospinal fluid concentration as a surrogate.
Kodaira H; Kusuhara H; Fujita T; Ushiki J; Fuse E; Sugiyama Y
J Pharmacol Exp Ther; 2011 Dec; 339(3):935-44. PubMed ID: 21934030
[TBL] [Abstract][Full Text] [Related]
33. The role of placental breast cancer resistance protein in the efflux of glyburide across the human placenta.
Pollex E; Lubetsky A; Koren G
Placenta; 2008 Aug; 29(8):743-7. PubMed ID: 18558430
[TBL] [Abstract][Full Text] [Related]
34. Transplacental transfer of melamine.
Partanen H; Vähäkangas K; Woo CS; Auriola S; Veid J; Chen Y; Myllynen P; El Nezami H
Placenta; 2012 Jan; 33(1):60-6. PubMed ID: 22082655
[TBL] [Abstract][Full Text] [Related]
35. Cyclosporin A affects the bioavailability of ginkgolic acids via inhibition of P-gp and BCRP.
Li L; Yao QQ; Xu SY; Hu HH; Shen Q; Tian Y; Pan LY; Zhou H; Jiang HD; Lu C; Yu LS; Zeng S
Eur J Pharm Biopharm; 2014 Nov; 88(3):759-67. PubMed ID: 24980806
[TBL] [Abstract][Full Text] [Related]
36. In vivo evaluation of P-glycoprotein and breast cancer resistance protein modulation in the brain using [(11)C]gefitinib.
Kawamura K; Yamasaki T; Yui J; Hatori A; Konno F; Kumata K; Irie T; Fukumura T; Suzuki K; Kanno I; Zhang MR
Nucl Med Biol; 2009 Apr; 36(3):239-46. PubMed ID: 19324269
[TBL] [Abstract][Full Text] [Related]
37. In vitro and in vivo evaluation of WK-X-34, a novel inhibitor of P-glycoprotein and BCRP, using radio imaging techniques.
Jekerle V; Klinkhammer W; Scollard DA; Breitbach K; Reilly RM; Piquette-Miller M; Wiese M
Int J Cancer; 2006 Jul; 119(2):414-22. PubMed ID: 16646006
[TBL] [Abstract][Full Text] [Related]
38. Differential sensitivities of the human ATP-binding cassette transporters ABCG2 and P-glycoprotein to cyclosporin A.
Ejendal KF; Hrycyna CA
Mol Pharmacol; 2005 Mar; 67(3):902-11. PubMed ID: 15598974
[TBL] [Abstract][Full Text] [Related]
39. P-glycoprotein and multidrug resistance protein activities in relation to treatment outcome in acute myeloid leukemia.
van der Kolk DM; de Vries EG; van Putten WJ; Verdonck LF; Ossenkoppele GJ; Verhoef GE; Vellenga E
Clin Cancer Res; 2000 Aug; 6(8):3205-14. PubMed ID: 10955805
[TBL] [Abstract][Full Text] [Related]
40. P-glycoprotein and breast cancer resistance protein influence brain distribution of dasatinib.
Chen Y; Agarwal S; Shaik NM; Chen C; Yang Z; Elmquist WF
J Pharmacol Exp Ther; 2009 Sep; 330(3):956-63. PubMed ID: 19491323
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
